Clinical pharmacokinetics of paclitaxel.
Paclitaxel is a new anticancer agent showing significant promise as therapy for solid tumours and leukaemia, given alone or in combination with other chemotherapeutic agents. Paclitaxel concentrations in biological specimens can be measured using high performance liquid chromatography, or more recently by immunoassay. Pharmacokinetic studies in which adults have been administered pacliaxel intravenously over 1 to 96 hours have demonstrated the following pharmacokinetic characteristics: extensive tissue distribution; high plasma protein binding (approximately 90 to 95%); variable systemic clearance, with average clearances ranging from 87 to 503 ml/min/m2 (5.2 to 30.2 L/h/m2); and minimal renal excretion of parent drug (< 10%). In vitro and in vivo studies have demonstrated that paclitaxel is extensively metabolised by the liver to 3 primary metabolites. Cytochrome P450 enzymes of the CYP3A and CYP2C subfamilies appear to be involved in hepatic metabolism of paclitaxel. Although early reports suggested that paclitaxel has first-order pharmacokinetics, some recent trials in children and adults suggest that its elimination is saturable. The clinical importance of saturable elimination would be greatest when large dosages are administered and/or the drug is infused over a shorter period of time. In these situations, achievable plasma concentrations are likely to exceed the affinity constant for elimination (Km). Thus, small changes in dosage or infusion duration may result in disproportionately large alterations in paclitaxel systemic exposure, potentially influencing patient response. A pharmacokinetic analysis of the combination of cisplatin and paclitaxel has demonstrated that paclitaxel clearance is apparently sequence dependent. Patients administered cisplatin prior to paclitaxel had lower clearances and greater clinical toxicity than patients receiving paclitaxel before cisplatin. Additional pharmacodynamic analyses have shown nonhaematological and haematological toxicity to correlate better with parameters of paclitaxel exposure (e.g. area under the plasma concentration-time curve, duration of plasma concentrations exceeding 0.1 mumol/L) than with the administered dosage.
Sonnichsen
D S
DS
Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis Tennessee.
Relling
M V
MV
D000042:Absorption; D000328:Adult; D001798:Blood Proteins / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D002851:Chromatography, High Pressure Liquid; D004304:Dosage Forms; D004333:Drug Administration Routes; D004359:Drug Therapy, Combination; D006801:Humans; D007118:Immunoassay; D017239:Paclitaxel / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D011485:Protein Binding; D014018:Tissue Distribution
D001798:Blood Proteins; D004304:Dosage Forms; D017239:Paclitaxel